HOTH - Hoth Therapeutics to initiate IND enabling studies of HT-001 in cancer

Hoth Therapeutics (HOTH) announces an agreement with Charles River Laboratories (CRL) to initiate preclinical studies of HT-001, a topical formulation designed for the treatment of rash and skin disorders associated with initial and repeat EGFR inhibitor cancer treatment.Together with Charles River Laboratories, Hoth has outlined six preclinical studies, the first bioanalytical method development studies beginning in Q1 2021.The initial studies will develop the required bioanalytical methods to perform GLP toxicology studies required by the FDA to initiate clinical studies for HT-001.At the Pre-IND Meeting, Hoth will discuss the required preclinical safety and toxicology studies and the full development plan of HT-001.

For further details see:

Hoth Therapeutics to initiate IND enabling studies of HT-001 in cancer